{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:42:23Z","timestamp":1790386943150,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1996,4,1]],"date-time":"1996-04-01T00:00:00Z","timestamp":828316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[1996,4]]},"DOI":"10.1016\/0959-8049(95)00616-8","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T19:10:36Z","timestamp":1027624236000},"page":"696-701","source":"Crossref","is-referenced-by-count":12,"title":["Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells"],"prefix":"10.1016","volume":"32","author":[{"given":"R.","family":"Hackenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hannig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schmidt-Rhode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-D.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/0959-8049(95)00616-8_BIB1","first-page":"384","article-title":"Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential","volume":"45","author":"Brodgen","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/0959-8049(95)00616-8_BIB2","first-page":"2851","article-title":"Antiprogestins, a new form of endocrine therapy for human breast cancer","volume":"49","author":"Klijn","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0022-4731(86)90314-6","article-title":"Studies on the mechanisms of action of progesterone antagonists","volume":"25","author":"Elger","year":"1986","journal-title":"J Steroid Biochem"},{"key":"10.1016\/0959-8049(95)00616-8_BIB4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9378(94)90468-5","article-title":"Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus","volume":"171","author":"Bigsby","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/0959-8049(95)00616-8_BIB5","first-page":"4595","article-title":"The effect of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture","volume":"36","author":"Lippman","year":"1976","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB6","first-page":"3352","article-title":"Establishment and characterization of three new continuous cell lines derived from human breast carcinomas","volume":"38","author":"Engel","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/1097-0142(19890515)63:10<1938::AID-CNCR2820631012>3.0.CO;2-S","article-title":"High-dose medroxyprogesterone-acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen","volume":"63","author":"Becher","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/0959-8049(95)00616-8_BIB8","first-page":"146","article-title":"The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?","volume":"13","author":"Horwitz","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/0959-8049(95)00616-8_BIB9","first-page":"359","article-title":"Effect of estrogen and progesterone on cellular replication of human breast tumors","volume":"42","author":"Dao","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1210\/endo-125-1-418","article-title":"Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D","volume":"125","author":"Hissom","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/0959-8049(95)00616-8_BIB11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1210\/jcem-56-6-1124","article-title":"Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture","volume":"56","author":"Vignon","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/0959-8049(95)00616-8_BIB12","first-page":"167","article-title":"Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47Dco human breast cancer cells by progestins: implications for endocrine therapies","volume":"45","author":"Horwitz","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF01613000","article-title":"Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary cancer cell growth","volume":"116","author":"Hackenberg","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/0959-8049(95)00616-8_BIB14","first-page":"4602","article-title":"The effect of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture","volume":"36","author":"Lippman","year":"1976","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01805942","article-title":"Androgens inhibit basal and estrogen-induced proliferatation in the ZR-75-1 human breast cancer cell line","volume":"12","author":"Poulin","year":"1988","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/0959-8049(95)00616-8_BIB16","first-page":"5722","article-title":"Androgen sensitivity of the new human breast cancer cell line MFM-223","volume":"51","author":"Hackenberg","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jnci\/73.2.313","article-title":"In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen and prolactin","volume":"73","author":"Simon","year":"1984","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/0959-8049(95)00616-8_BIB18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00689836","article-title":"Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor","volume":"25","author":"Hackenberg","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/0959-8049(95)00616-8_BIB19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0960-0760(93)90187-2","article-title":"Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3\u03b2, 17b-diol in human mammary cancer cells","volume":"46","author":"Hackenberg","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/0959-8049(95)00616-8_BIB20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0022-4731(85)90136-0","article-title":"Onset of androgen action in MCF-7 human breast cancer cells is not accompanied by receptor depletion","volume":"22","author":"Shapiro","year":"1985","journal-title":"J Steroid Biochem"},{"key":"10.1016\/0959-8049(95)00616-8_BIB21","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/MCB.11.6.3247","article-title":"Functional interaction of hybrid response elements with wild type and mutant steroid hormone receptor","volume":"11","author":"Truss","year":"1991","journal-title":"Mokec Cell Biol"},{"key":"10.1016\/0959-8049(95)00616-8_BIB22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ijc.2910570121","article-title":"Androgen responsiveness of the new endometrial cancer cell line MFE-296","volume":"57","author":"Hackenberg","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/0959-8049(95)00616-8_BIB23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/dna.1992.11.83","article-title":"An improved CAT assay for promotor analysis in either transgenic mice or tissue culture cells","volume":"11","author":"Pothier","year":"1992","journal-title":"DNA Cell Biol"},{"key":"10.1016\/0959-8049(95)00616-8_BIB24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1055\/s-2008-1026636","article-title":"Antigestagene","volume":"48","author":"van Uem","year":"1988","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/0959-8049(95)00616-8_BIB25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1210\/jcem-60-4-692","article-title":"RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor","volume":"60","author":"Bardon","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/0959-8049(95)00616-8_BIB26","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1210\/endo-116-6-2236","article-title":"The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells","volume":"116","author":"Horwitz","year":"1985","journal-title":"Endocrinology"},{"key":"10.1016\/0959-8049(95)00616-8_BIB27","first-page":"1441","article-title":"Steroid-receptor-mediated cytotoxicity of an antioestrogen and an anti-progestin in breast cancer cells","volume":"47","author":"Bardon","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/0959-8049(95)00616-8_BIB28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01806133","article-title":"Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells","volume":"10","author":"Gill","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/0959-8049(95)00616-8_BIB29","first-page":"4441","article-title":"The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways","volume":"90","author":"Beck","year":"1993"},{"key":"10.1016\/0959-8049(95)00616-8_BIB30","first-page":"3938","article-title":"Ionic and ligand-specific effects on the DNA binding of progesterone receptor bound the synthetic progestin R5020 and the antiprogestin RU486","volume":"51","author":"Chao","year":"1991","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0959804995006168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0959804995006168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T23:26:35Z","timestamp":1555975595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0959804995006168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["0959804995006168"],"URL":"https:\/\/doi.org\/10.1016\/0959-8049(95)00616-8","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}